Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving the personalized neoantigen peptide-based vaccine with pem

Trial Details

NCT ID
NCT05269381
Phase
PHASE1 / PHASE2
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Cyclophosphamide
  • Neoantigen Peptide Vaccine
  • Pembrolizumab
  • Sargramostim
  • Biospecimen Collection
  • Biopsy
Locations (sample)
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • PHASE I PRE-REGISTRATION, ALL:
  • Willing to provide tissue specimens per protocol, or have clinically collected formalin-fixed paraffin-embedded (FFPE) tissue blocks, or available …
  • NOTE 1: Includes fresh tissue specimen at pre-registration, or with or clinically collected FFPE tissue blocks for complete exome and transcriptome…
  • NOTE 2: This criteria will not apply to patients who had sequencing and neoantigen prediction previously completed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →